Sarepta Therapeutics is Crazy!!

Mar 25, 2018
Sarepta has been pursuing strategic collaborations for the development of its disease- modifying DMD pipeline ever since it gained approval for Exondys 51.

Its quarterly revenue growth was 956.60%, super awesome!!

If you look at its performance, its stock price is higher and higher.

Do you think it will continue to rise, will you invest it?